These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1694090)

  • 1. Leu-19 in myeloma--a new role for an old antibody.
    Wetter O; Brandhorst D; Reiter W
    Eur J Cancer; 1990 Apr; 26(4):541. PubMed ID: 1694090
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
    Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
    Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.
    Leo R; Boeker M; Peest D; Hein R; Bartl R; Gessner JE; Selbach J; Wacker G; Deicher H
    Ann Hematol; 1992 Mar; 64(3):132-9. PubMed ID: 1373957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.
    Hata H; Matsuzaki H; Matsuno F; Sonoki T; Takemoto S; Kuribayashi N; Nagasaki A; Takatsuki K
    Clin Exp Immunol; 1994 May; 96(2):370-5. PubMed ID: 8187346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotyping primitive plasma cells.
    Joshua D; Pope B; Brown R; Brown L; Murray A; Gibson J
    Br J Haematol; 2002 Apr; 117(1):252-3. PubMed ID: 11918567
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of peripheral blood myeloma cells by three-color flow cytometry.
    Witzig TE; Kimlinger TK; Greipp PR
    Curr Top Microbiol Immunol; 1995; 194():3-8. PubMed ID: 7895502
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.
    Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A
    Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma with coexpression of myeloid and natural killer cell antigens.
    Drach J; Gattringer C; Huber H
    Blood; 1990 Jul; 76(1):265-6. PubMed ID: 1694700
    [No Abstract]   [Full Text] [Related]  

  • 9. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.
    Bergsagel PL; Smith AM; Szczepek A; Mant MJ; Belch AR; Pilarski LM
    Blood; 1995 Jan; 85(2):436-47. PubMed ID: 7529064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease.
    Nowak R; Oelschlägel U; Range U; Mölle M; Ehninger G
    Am J Clin Pathol; 1998 Feb; 109(2):226-32. PubMed ID: 9583896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of natural-killer-associated and activation antigens in multiple myeloma.
    Gonzalez M; San Miguel JF; Gascon A; Moro MJ; Hernandez JM; Ortega F; Jimenez R; Guerras L; Romero M; Casanova F
    Am J Hematol; 1992 Feb; 39(2):84-9. PubMed ID: 1550111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myeloma precursor cells].
    Iwato K; Kawano MM
    Rinsho Ketsueki; 1993 Apr; 34(4):433-8. PubMed ID: 7685432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma: expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation.
    Petersen AJ; Brown RD; Pope BB; Jamieson GP; Paterson AR; Gibson J; Wiley JS; Joshua DE
    Leuk Lymphoma; 1994 May; 13(5-6):491-9. PubMed ID: 8069194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clonal hierachy in multiple myeloma.
    Rasmussen T; Jensen L; Johnsen HE
    Acta Oncol; 2000; 39(7):765-70. PubMed ID: 11145430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma: relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytes.
    Joshua DE; Ioannidis R; Brown R; Francis SE; Gibson J; Kronenberg H
    Am J Hematol; 1988 Sep; 29(1):5-11. PubMed ID: 3052044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of CD56 and HLA/DR antigens in CD2+ cells from multiple myeloma patients.
    Lapeña P; Prieto A; Garcia-Suarez J; Reyes E; San Miguel J; Jorda J; Alvarez-Mon M
    Am J Hematol; 1994 Jun; 46(2):158-9. PubMed ID: 7513496
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
    Kimlinger T; Witzig TE
    Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of CD38 as target for immunotherapy in multiple myeloma.
    Vooijs WC; Schuurman HJ; Bast EJ; de Gast GC
    Blood; 1995 Apr; 85(8):2282-4. PubMed ID: 7718903
    [No Abstract]   [Full Text] [Related]  

  • 20. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
    Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
    Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.